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Abstract
Background: Evidence supported a beneficial effect of ivabradine on clinical outcome of pa-
tients with systolic heart failure, and a sinus heart rate (HR) ≥ 70 bpm. We explored the effect 
of ivabradine, vs. placebo, added to evidence-based treatment on exercise tolerance and quality 
of life in patients with idiopathic dilated cardiomyopathy.
Methods: We enrolled 43 consecutive patients with dilated cardiomyopathy of no apparent 
cause, a left ventricular ejection fraction (LVEF) < 40%, New York Heart Association class ≥ II,  
sinus HR ≥ 70 bpm, and background evidence-based anti-failure medications. Ischemic  
heart disease was ruled out. Patients were randomized (1:1) to receive ivabradine or  
placebo. Ivabradine was titrated up gradually till 7.5 mg twice daily, or a HR < 60 bpm,  
and continued for 3 months. Symptom-limited exercise tolerance test was performed, and qual-
ity of life was assessed by the Minnesota Living With Heart Failure Questionnaire at 0, and 
3 months.
Results: Forty-three patients were randomized to ivabradine (n = 20), or placebo (n = 23). 
Mean age was 50.8 ± 14.5 years (53.5% males). Mean HR was 85 ± 12 bpm, and mean 
LVEF was 32 ± 6%. Mean dose of carvedilol was 31.2% of the target dose. Baseline HR, 
blood pressure, exercise tolerance, Minnesota questionnaire score, and left ventricular systolic 
function were comparable between the two groups (p > 0.05 for all). At 3 months, mean dose 
of ivabradine was 6.8 mg bid. Ivabradine-treated patients had a lower HR, and improved left 
ventricular dimensions and systolic function, versus placebo-treated ones (p < 0.05 for all). 
HR dropped by a mean of 14 bpm in the ivabradine group, corrected for placebo. Both exercise 
tolerance, and Minnesota questionnaire score were better in the ivabradine group (p < 0.05 
both). Ivabradine was well-tolerated.
Conclusions: In symptomatic patients with idiopathic dilated cardiomyopathy, the addition 
of ivabradine, vs. placebo, to evidence-based treatment, reduced HR, and improved functional 
capacity, at short-term follow-up. (Cardiol J 2015; 22, 2: 227–232)
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Introduction
Heart rate (HR) reduction improves left ven-
tricular (LV) diastolic filling, reduces myocardial 
oxygen consumption, and increases coronary perfu-
sion time. Ivabradine reduces HR by selectively in-
hibiting If current in the sinoatrial node pacemaker 
cells, in a dose-dependent manner [1]. In patients 
with chronic stable angina, ivabradine improved 
exercise tolerance, vs. placebo [2], was non-inferior 
to atenolol and amlodipine for improving total 
exercise duration and decreasing the frequency of 
anginal attacks at 3-month follow-up [3, 4].
In an animal model of ischemia-induced heart 
failure (HF), HR reduction with ivabradine im-
proved LV systolic function, an effect that per-
sisted after drug withdrawal, possibly mediated by 
modification of LV structure and myocyte function 
resulting from chronic HR reduction [5]. Moreover, 
in patients with idiopathic dilated cardiomyopathy, 
ivabradine proved safe and effective for HR reduc-
tion at short-term follow-up [6]. Yet, evidence is 
limited on the effect of ivabradine on the functional 
capacity of these patients. In a prospective rand-
omized study design, we tested the hypothesis 
that the administration of ivabradine, vs. placebo, 
as add-on therapy to evidence-based medical treat-
ment would improve the exercise tolerance and 
quality of life at short-term follow-up, in patients 
with idiopathic dilated cardiomyopathy.
Methods
Patient selection
We conducted a randomized, double-blinded, 
placebo-controlled, parallel-arm trial to explore 
the effect of ivabradine, vs. placebo, as add-on 
therapy to optimal medical treatment on the ex-
ercise tolerance and quality of life, in patients 
with idiopathic dilated cardiomyopathy. Patients 
were recruited from the outpatient clinic during 
the period from July 2011 to March 2012. Eligible 
patients were above 18 years, confirmed to have 
dilated cardiomyopathy with no apparent cause, 
with a left ventricular ejection fraction (LVEF) 
< 40%, New York Heart Association (NYHA) 
class ≥ II, in sinus rhythm with a resting HR ≥ 70 bpm, 
who were symptomatic for at least 4 weeks. Patients 
needed to be on stable, background evidence-based 
medications of HF (maximally tolerated doses 
of carvedilol, angiotensin converting enzyme in-
hibitors [ACEI], and spironolactone) for at least 
4 weeks. Ischemic heart disease was ruled out based 
on previous history of myocardial infarction, prior 
coronary revascularization, coronary angiogram 
showing at least 50% stenosis in at least one sizable 
coronary artery, or negative myocardial perfusion 
imaging for exercise-induced myocardial ischemia. 
Exclusion criteria included atrial fibrillation/flutter, 
pacemaker or cardiac resynchronization therapy, 
second or third degree atrioventricular block, se-
rum transaminases > 3 times the upper reference 
limit, serum creatinine > 2 mg/dL, hemoglobin 
< 10 mg/dL, uncontrolled thyroid disease, recent 
treatment with amiodarone, significant valvular or 
congenital heart disease, pregnancy, and inability 
to perform exercise tolerance test.
Study design
Before inclusion, informed written consent 
was obtained from each patient, and the study 
protocol was reviewed and approved by our Institu-
tional Human Research Committee as it conforms 
to the ethical guidelines of the 1975 Declaration 
of Helsinki, as revised in 2002. Qualifying patients 
were randomly assigned (1:1 ratio) to receive either 
ivabradine (Procoralan®, Servier, France) as add-on 
therapy or placebo. Randomization was performed 
by computer-generated allocation schedule drawn 
by an independent statistician. Ivabradine was initi-
ated at a dose of 2.5 mg once daily for the first week, 
2.5 mg twice daily for the second week, and then 
titrated up by 2.5 mg increments every week till 
a maximal dose of 7.5 mg twice daily, or a drop of HR 
< 60 bpm. Study drugs were identical in appearance. 
Patients remained in the same allocation, and stand-
ard medications of HF remained unchanged through-
out the study period. Treatment was continued for 
3 months. Both the patients and the investigators 
performing the baseline and follow-up assessment 
were blinded to the treatment allocation.
Echocardiographic assessment
Assessment of LV systolic function was per-
formed by trans-thoracic echocardiography at day 
0, and at the end of 3 months. Doppler echocar-
diography was performed using a General Elec-
tric Vivid 7 Pro cardiac ultrasound machine (GE 
Medical Systems, Horten, Norway). A 3.5 MHz 
phased-array transducer was used to obtain stand-
ard 2 dimensional (2-D), M-mode, and Doppler 
flow. Patients were examined in the left lateral 
recumbent position using standard parasternal 
and apical views. LV systolic function was as-
sessed by M-mode in parasternal long-axis view 
using the Teichholz method, and by 2-D in apical 
2- and 4-chamber views using the biplane modified 
Simpson’s method. Cardiac chamber quantification 
was performed as recommended by the American 
Society of Echocardiography [7].
228 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 2
Exercise tolerance test
Symptom-limited exercise tolerance test was 
performed according to the modified Bruce proto-
col [8] at day 0, and at the end of 3 months. Patients 
were examined after 4 h fast, and abstinence from 
smoking, alcohol, and caffeine for at least 2 h. 
Reasons for termination were limiting dyspnea or 
extreme fatigue. The total exercise duration was 
calculated.
Quality of life assessment
The quality of life was assessed by the Min-
nesota Living With Heart Failure Questionnaire, 
based on 21 questions that refer to symptoms 
of HF, physical and sexual activity, work, social 
relationships, and emotions. The answer for each 
question was chosen from a scale of 0 (none) to 5 
(very much); the greater the score, the worse the 
quality of life [9]. Assessment was performed at 
day 0 and at the end of 3 months.
Statistical analysis
Continuous variables were presented as mean 
± standard deviation, if they were normally dis-
tributed. Data were tested for normal distribution 
using the Kolmogorov-Smirnov test. Categorical 
variables were described with absolute and relative 
(percentage) frequencies. Comparisons between 
the two groups were performed using the unpaired 
t-test or Mann-Whitney test for continuous vari-
ables, and Pearson’s c2 or Fisher’s Exact test for 
categorical variables, as appropriate. Pearson’s 
correlation coefficient test was performed to 
study the correlation between HR at 3 months 
on one hand; and exercise tolerance and quality 
of life, on the other hand. All tests were 2-sided 
and a probability value of p < 0.05 was considered 
statistically significant. Analyses were performed 
with SPSS version 16.0 statistical package (SPSS 
Inc., Chicago, IL, USA).
Results
Baseline clinical characteristics
A total of 43 consecutive symptomatic patients 
with idiopathic dilated cardiomyopathy were ran-
domized to receive ivabradine as add-on therapy 
(n= 20), or placebo (n= 23), and completed 
follow-up for 3 months. Mean age of the study 
cohort was 50.8 ± 14.5 years; 23 (53.5%) patients 
were males. Mean HR was 85 ± 12 bpm, and mean 
LVEF was 32% ± 6 by both M-mode and 2-D 
measurements. At baseline, 9 (20.9%) patients 
were in NYHA class II, 26 (60.5%) patients in 
class III, and 8 (18.6%) patients in class IV. All pa-
tients received carvedilol as a beta-blocker. The 
median (range) dose of carvedilol was 9.375 mg 
daily (6.25–12.5 mg daily). Forty (93%) patients 
received captopril as an ACEI; 3 (7%) patients 
received enalapril. The median (range) dose 
of captopril was 37.5 mg daily in three divided 
doses (18.75–100 mg daily). All patients received 
spironolactone as an aldosterone antagonist at 
a dose of 25 mg daily. The mean dose of carve-
dilol was 31.2 ± 26.8% of the target dose and 
mean dose of ACEI was 70.5 ± 24.8% of the 
target dose, as defined by the European Society 
of Cardiology guidelines [10]. The main rea-
sons for patients not receiving target doses of 
carvedilol were hypotension, asthma, chronic 
obstructive airway disease, and fatigue; and 
the main reasons for not receiving target doses 
of ACEI were hypotension and severe dizzi-
ness. Table 1 shows the baseline clinical char-
acteristics of the two groups. Baseline HR, 
blood pressure, exercise tolerance, Minnesota 
questionnaire score, and LV systolic function 
were all comparable between the two groups 
(p > 0.05 for all) (Table 2).
Clinical outcome at 3-month follow-up
At the end of a 3-month follow-up, 16 (80%) 
patients of the ivabradine group were on 7.5 mg 
twice daily, 3 (15%) on 5 mg twice daily, and 1 (5%) 
on 2.5 mg once daily (severe visual symptoms). The 
mean dose of ivabradine received was 6.8 mg twice 
daily. The main reasons for patients not reaching 
the target dose of ivabradine were symptomatic 
bradycardia, and visual symptoms (phosphenes). 








Age [years] 49.1 ± 15.7 52.3 ± 13.5
Male gender 10 (50%) 13 (56.5%)
Smoking 2 (10%) 3 (13%)
Hypertension 5 (25%) 4 (17.4%)
Diabetes mellitus 4 (20%) 5 (21.7%)
ACEI of target  
dose [%]
66.7 ± 24.1 73.9 ± 25.5
Carvedilol  
dose [mg]
18.9 ± 16.2 12.8 ± 10
Continuous variables are presented as mean ± standard deviation, 
whereas categorical variables are presented as frequency (percent-
age); ACEI — angiotensin converting enzyme inhibitors
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At 3 months, ivabradine-treated patients had a lower 
HR, and improved LV dimensions and systolic func-
tion compared with placebo-treated ones (p < 0.05 
for all). At follow-up, HR was reduced by a mean 
of 17 bpm in the ivabradine group compared with 
baseline; when corrected for such reduction in the 
placebo group, the net HR reduction in the ivabra-
dine group was 14 bpm. Both exercise tolerance, 
and Minnesota questionnaire score were better 
in the ivabradine group (p < 0.05 for both). Yet, 
NYHA class and blood pressure were comparable 
in the two groups (Table 2). At the end of follow-
up, resting HR correlated negatively with the total 
exercise duration (r = –0.377, p = 0.024) (Fig. 1), 
and positively with Minnesota questionnaire score 
(r = 0.316, p = 0.047) (Fig. 2).
One (5%) patient in the ivabradine group was 
hospitalized for worsening HF (defined as new or 
increasing symptoms and signs of HF, with evidence 
of fluid retention), vs. 2 (8.7%) in the placebo group. 
One patient in either group died of decompensated 
HF. Symptomatic bradycardia occurred in 3 (15%) 
patients in the ivabradine group, and visual symp-
toms (phosphenes) in 1 (5%). No one in the placebo 
group developed such adverse effects.
Discussion
Major findings
The current pilot study demonstrated that in 
symptomatic patients with idiopathic dilated car-
diomyopathy who are already receiving the maxi-
mally tolerated doses of beta-blockers and ACEI, 
the administration of ivabradine as add-on therapy 
reduced HR, improved LV systolic function, exer-
cise tolerance, and quality of life, compared with 
placebo, at short-term follow-up. Yet, no effect on 
blood pressure or NYHA class was observed. To 
the best of the authors’ knowledge, this is the first 
piece of evidence for a beneficial effect of ivabra-
dine on exercise tolerance and quality of life in 
patients with non-ischemic cardiomyopathy.
Heart rate reduction as a therapeutic target
Increased resting HR is a known risk fac-
tor for worse clinical outcome in patients with 
HF, and chronic stable angina [11, 12]. Evidence 
suggests that HR reduction is associated with 
improved clinical outcome in patients with HF 
and LV systolic dysfunction [13]; the magnitude 
of benefit is related to the extent of HR reduction 
















NYHA class: > 0.05 > 0.05
    I 0 (0%) 0 (0%) 2 (10%) 0 (0%)
    II 6 (30%) 5 (21.7%) 12 (60%) 12 (52.2%)
    III 12 (60%) 14 (60.9%) 5 (25%) 8 (34.8%)
    IV 2 (10%) 4 (17.4%) 1 (5%) 3 (13%)
Resting heart rate [bpm] 85 ± 12 84 ± 10 > 0.05 68 ± 11 81 ± 13 < 0.05
Systolic BP [mm Hg] 101 ± 17 91 ± 5 > 0.05 100 ± 17 89 ± 6 > 0.05
Diastolic BP [mm Hg] 69 ± 12 61 ± 4 > 0.05 63 ± 10 61 ± 4 > 0.05
LV EDD [mm] 66 ± 6 70 ± 5 > 0.05 61 ± 7 70 ± 7 < 0.05
LV ESD [mm] 56 ± 6 59 ± 6 > 0.05 49 ± 7 58 ± 7 < 0.05
M-mode EF [%] 32 ± 7 32 ± 5 > 0.05 38 ± 10 34 ± 7 > 0.05
LV EDV [mL] 171 ± 35 184 ± 44 > 0.05 150 ± 32 190 ± 62 < 0.05
LV ESV [mL] 113 ± 26 126 ± 31 > 0.05 92 ± 27 130 ± 41 < 0.05
Two-dimensional EF [%] 34 ± 4 30 ± 8 > 0.05 39 ± 7 33 ± 10 < 0.05
Left atrial diameter [mm] 42 ± 6 47 ± 5 > 0.05 41 ± 5 47 ± 5 < 0.05
Total exercise duration ≥ 6 min 5 (25%) 6 (26.1%) > 0.05 12 (60%) 7 (30.4%) < 0.05
Minnesota questionnaire score 58.8 ± 7.2 60.3 ± 5.5 > 0.05 46.4 ± 7.3 51.7 ± 6.6 < 0.05
Continuous variables are presented as mean ± standard deviation, whereas categorical variables are presented as frequency (percentage); 
NYHA — New York Heart Association; BP — blood pressure; LV — left ventricular; EDD — end-diastolic dimension; ESD — end-systolic  
dimension; EF — ejection fraction; EDV — end-diastolic volume; ESV — end-systolic volume
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[11, 14]. Unfortunately, in most patients with HF 
receiving beta-blockers, HR remains substantially 
elevated [15]. In this context, selective If cur-
rent inhibition with ivabradine has emerged as 
a promising therapeutic approach in these patients. 
In the multicenter randomized placebo-controlled 
SHIFT trial, ivabradine reduced the composite 
endpoint of cardiovascular death or hospitalization 
for HF, at long-term, in patients with systolic HF 
(67.5% ischemic, 56% prior myocardial infarction) 
and a sinus HR ≥ 70 bpm, a benefit largely driven 
by reduction of HF hospitalization [16]. This was 
the main drive for the 2012 updated guidelines of 
the European Society of Cardiology to consider 
ivabradine for reduction of HF hospitalization 
in patients with symptomatic HF, LVEF ≤ 35%, 
and a sinus HR ≥ 70 bpm, despite the maximally 
tolerated doses of evidence-based therapy (class IIa, 
level of evidence B), and in patients unable to 
tolerate a beta-blocker (class IIb, level of evi-
dence C) [10]. Improvement of clinical outcome 
in the SHIFT trial was associated with improve-
ment of the NYHA class, and both patient- and 
physician-reported assessment of quality of life 
[16]. Similarly, in the CARVIVA HF trial, ivabra-
dine — alone or in combination with carvedilol 
— improved exercise tolerance and quality of 
life, vs. carvedilol alone, in patients with HF 
(81% ischemic) [17]. The current study serves 
to support and extend these results to patients 
with idiopathic dilated cardiomyopathy whose 
HF is non-ischemic in origin.
Heart rate reduction with ivabradine
In the current study, the mean dose of beta-
blockers received by patients was far from the 
target dose recommended by the guidelines of the 
European Society of Cardiology (31.2%). This was 
mainly due to intolerance to beta-blockers. Not 
surprisingly, the mean baseline HR was 85 bpm. 
Likewise, in the SHIFT trial, only 26% of patients 
received the target dose of beta-blockers (56% re-
ceived ≥ 50% of target dose), and the mean HR was 
80 bpm [16]. The mean HR reduction — corrected 
for placebo — in the current study was 14 bpm at 
3 months (mean ivabradine dose 6.8 mg), compared 
with 11 bpm at 28 days (mean ivabradine dose 
6.5 mg) in the SHIFT trial [16]. In the current study, 
the magnitude of benefit in terms of exercise toler-
ance and quality of life correlated with the final HR 
at follow-up. The extent of HR reduction, rather 
than background beta-blocker dose, accounted for 
the effect of ivabradine on clinical outcome in the 
SHIFT trial [11, 14]. Yet, lack of statistically signifi-
cant improvement of the NYHA class in the current 
study might be due to the small sample size.
Heart rate reduction with ivabradine was asso-
ciated with maintenance of systolic blood pressure, 
possibly due to improved stroke volume. This is 
supported by the improvement of LV dimensions 
and LVEF. In a rat model of ischemia-induced 
HF, ivabradine improved LV systolic function and 
stroke volume, and preserved cardiac output at 
90-day follow-up, despite HR reduction [5]. In that 
study, improvement was related not only to HR 
reduction, but also to modification of extracellular 
matrix, and cardiac myocyte function, as result of 
sustained HR reduction [5].
Figure 1. Correlation between resting heart rate (HR) 
and the total exercise duration at 3-month follow-up.
Figure 2. Correlation between resting heart rate (HR) 
and Minnesota questionnaire score at 3-month follow-up.
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Clinical implications
Evidence supported a beneficial effect of 
ivabradine on the long-term clinical outcome of 
patients with systolic HF (predominantly ischemic) 
in whom sinus HR remains ≥ 70 bpm [16], and 
on the ischemia-related outcome of patients with 
stable angina, LV systolic dysfunction, and a sinus 
HR ≥ 70 bpm [18]. The ongoing SIGNIFY trial 
examines the effect of ivabradine, vs. placebo, on 
the clinical outcome in patients with stable angina, 
normal ejection fraction, and no HF [19]. The 
current study suggested that ivabradine may be 
considered to improve functional capacity and LV 
systolic function in patients with non-ischemic HF 
due to idiopathic dilated cardiomyopathy. Further 
large-scale randomized trials are needed to explore 
the effect of ivabradine vs. placebo on the long-term 
clinical outcome in such patients.
Limitations of the study
Our findings are based on a single-center study 
with a rather small sample size, and relatively short 
follow-up. Therefore, our results should be taken 
with caution. Moreover, most patients were not re-
ceiving the target doses of evidence-based therapy. 
Hence, our results cannot be generalized to patients 
on the target doses of background therapy. Addition-
ally, we excluded patients with device therapy. The 
effect of ivabradine in such subset needs further 
exploration. Finally, we enrolled patients with 
a sinus HR ≥ 70 bpm, therefore, our findings do not 
apply to patients with atrial fibrillation/flutter.
Conclusions
In symptomatic patients with idiopathic di-
lated cardiomyopathy who are already receiving 
the maximally tolerated doses of evidence-based 
treatment, the addition of ivabradine, vs. placebo, 
reduced HR and improved functional capacity at 
short-term follow-up.
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